$RADX

Radiopharm completes Phase 2b enrollment for brain imaging agent RAD 101 with 90% MRI concordance, initiates new trials while cash reserves fall sharply.

Radiopharm Theranostics advances RAD202 radiopharmaceutical trial to higher dose cohort following positive safety review, remaining on track for 2026 Phase 1 completion.

Radiopharm Theranostics and Siemens Healthineers sign manufacturing supply agreement for RAD101 PET imaging agent, advancing toward Phase 3 trial with strong interim data.

Radiopharm Theranostics doses first patient in Phase 1 trial of RAD 402, a targeted radioimmune therapy for advanced prostate cancer, with data expected H2 2026.